{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/chronic-kidney-disease/","result":{"data":{"firstChapter":{"id":"5036566c-74da-5f5a-8ad0-52200f66bacc","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field e4cf91a9-38f7-4ec3-b7fe-4a9da3d2e89f --><h1>Chronic kidney disease: Summary</h1><!-- end field e4cf91a9-38f7-4ec3-b7fe-4a9da3d2e89f -->","htmlStringContent":"<!-- begin item f4d1b344-1309-4c13-9af6-1b26cdb1e728 --><!-- begin field 1128c90a-2e96-447e-90e8-407a98340546 --><ul><li>Chronic kidney disease (CKD) is a reduction in kidney function or structural damage (or both) present for more than 3 months, with associated health implications.</li><li>CKD should be diagnosed in people with:<ul><li>Markers of kidney damage such as proteinuria (urinary albumin:creatinine ratio [ACR] greater than 3 mg/mmol), urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders, abnormalities detected by histology, structural abnormalities detected by imaging, and a history of kidney transplantation, and/or</li><li>A persistent reduction in renal function shown by a serum estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m<sup>2</sup>.</li></ul></li><li>CKD is classified based on the underlying cause, GFR, and proteinuria category.</li><li>There are multiple possible causes and risk factors for CKD and its progression, including hypertension, diabetes mellitus, cardiovascular disease (CVD), acute kidney injury (AKI), nephrotoxic drugs, and obstructive uropathy.</li><li>The risk of complications from CKD increases with disease progression and include AKI, hypertension, CVD, renal anaemia, renal mineral and bone disorder, end-stage renal disease (ESRD), and increased all-cause mortality.</li><li>CKD should be suspected in people with:<ul><li>Risk factors for CKD.</li><li>An incidental finding of raised serum creatinine and/or eGFR of less than 60 mL/min/1.73 m<sup>2</sup>; or markers of kidney damage.</li><li>Possible clinical features of CKD (rare unless end-stage disease).</li></ul></li><li>If a diagnosis of CKD is suspected, initial investigations should be arranged and repeated as appropriate:<ul><li>Serum creatinine and eGFR.</li><li>Early morning urine sample to measure the ACR.</li><li>Urine dipstick test to check for haematuria.</li><li>Body mass index (BMI), blood pressure, and serum HbA1c and lipid profile to assess for cardiovascular risk factors.</li><li>A renal tract ultrasound if indicated, such as suspected urinary tract stones or obstruction, or a family history of polycystic kidney disease.</li></ul></li><li>If CKD is confirmed, monitoring for disease progression should include:<ul><li>Measuring eGFR and urine ACR, a full blood count to exclude renal anaemia, and serum calcium, phosphate, vitamin D, and parathyroid hormone tests to exclude renal metabolic and bone disorder, depending on the severity of CKD.</li></ul></li><li>Referral to a nephrology specialist should be arranged if there is:<ul><li>An eGFR of less than 30 mL/min/1.73 m<sup>2</sup>.</li><li>Accelerated progression of CKD.</li><li>A urinary ACR of 70 mg/mmol or more, unless known to be associated with diabetes mellitus.</li><li>A urinary ACR of 30 mg/mmol or more together with persistent haematuria, after exclusion of a urinary tract infection (UTI).</li><li>Uncontrolled hypertension.</li><li>A rare or genetic cause of CKD.</li><li>Suspected renal artery stenosis.</li><li>A suspected complication of CKD.</li></ul></li><li>Management in primary care should include:<ul><li>Providing sources of information, advice, and support.</li><li>Assessing for and managing risk factors and co-morbidities.</li><li>Advising on healthy lifestyle measures and avoiding the use of over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs).</li><li>Assessing for hypertension and CVD, and managing appropriately.</li><li>Prescribing a low-cost renin-angiotensin system antagonist, if appropriate.</li><li>Ensuring the person is offered immunizations for influenza and pneumococcal disease.</li></ul></li></ul><!-- end field 1128c90a-2e96-447e-90e8-407a98340546 --><!-- end item f4d1b344-1309-4c13-9af6-1b26cdb1e728 -->","topic":{"id":"cf2598e6-fd50-5f3b-8ae0-aad8ebd19ed8","topicId":"ae266062-cc1b-44e2-8118-44e1890750e3","topicName":"Chronic kidney disease","slug":"chronic-kidney-disease","aliases":["Kidney disease - chronic"],"chapters":[{"id":"5036566c-74da-5f5a-8ad0-52200f66bacc","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5b4e7fb9-e75e-5183-b93f-5121d902b8aa","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"75479619-9bb3-51b1-8d45-322a0183327c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"85bf4dec-7d92-5c07-9468-68fd460fa54c","slug":"changes","fullItemName":"Changes"},{"id":"e9caee39-e4d7-55ea-bba5-d1bfb037fab3","slug":"update","fullItemName":"Update"}]},{"id":"94be5ea4-6a52-53bd-9cff-cbc58599fb38","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"af9d912d-8cc7-598f-90cf-201a0152486f","slug":"goals","fullItemName":"Goals"},{"id":"e04a2acd-d3aa-5b29-afe8-4ff8a5cf2527","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c36c8ae1-59b3-5370-8b7b-c879c1c25d17","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb64e97-bb95-5733-ba72-d5da80477d5b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0cefa383-4a3f-5e37-8c1d-0cc7b2ba971c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c308ef71-7be3-579d-9b92-dd1e9164c74d","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"34f1f543-1b43-52aa-91e6-43d392ace4b2","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"420f2db7-0bb3-5f08-a35d-671ffd9e83db","slug":"definition","fullItemName":"Definition"},{"id":"f36e5c98-76d5-563f-b7e3-a8e580d8edda","slug":"causes","fullItemName":"Causes"},{"id":"16745b88-79f5-5576-a0a4-704c8cb342e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82584375-f9fb-5690-9fe3-f2fb2586f2de","slug":"complications","fullItemName":"Complications"},{"id":"6ddacff5-19b6-5342-b340-25aecbf26dbd","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00dbd4ad-decc-5bde-b4a3-2599d730c702","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"cdd9f22d-7a2f-5fd6-a9e1-199b0c3ffdfa","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c6b6c8c3-633d-5062-9804-7b6711e7ddcd","slug":"assessment","fullItemName":"Assessment"},{"id":"3878fa85-9973-5158-8407-20d64dbf148d","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"579baee5-96e6-5639-a5ee-7dc30540dc8f","slug":"management","fullItemName":"Management","subChapters":[{"id":"07ec0bcd-8fb7-5ae7-87fd-2ff471574c5c","slug":"management-of-chronic-kidney-disease","fullItemName":"Scenario: Management of chronic kidney disease"},{"id":"44ceaa7d-a91b-5472-a7ab-e4bc448067ad","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"b0158ce5-7a78-50df-8843-ded7d59d08e3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"a270530d-7db1-5b03-a1d8-8ff38e242ab9","slug":"ace-inhibitors-aiiras","fullItemName":"ACE-inhibitors and AIIRAs"}]},{"id":"50985320-3b22-5997-85d2-680285318de6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"168ee77d-eb0d-52d8-a32b-4bda877d21f0","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c8ca80a7-ccf2-5a42-9b8e-72783e1f2131","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fe26a3ba-fa1b-5c97-8a08-e1f7d193447a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"854a26b2-4877-59ae-863e-99abcbcad667","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0af4d212-648e-5a4d-ad67-b1874a49688e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f180e32d-a855-558d-b666-d4c6804afe04","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ba009e6c-4065-55da-b6c5-bd179af81374","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"cf2598e6-fd50-5f3b-8ae0-aad8ebd19ed8","topicId":"ae266062-cc1b-44e2-8118-44e1890750e3","topicName":"Chronic kidney disease","slug":"chronic-kidney-disease","aliases":["Kidney disease - chronic"],"topicSummary":"Chronic kidney disease (CKD) is an abnormality of kidney function or structure that is present for more than 3 months, with implications for health","lastRevised":"Last revised in May 2020","nextPlannedReviewBy":"2024-03-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2024-03","nextPlannedReviewByDisplay":"March 2024","specialities":[{"id":"fe645ae3-9536-5dfb-8c84-285b62195550","name":"Cardiovascular","slug":"cardiovascular"},{"id":"aa304738-44fc-5b1d-af3b-42cce5d27663","name":"Endocrine and metabolic","slug":"endocrine-metabolic"},{"id":"f72b3ad6-0501-5364-8469-e48bd9b988b9","name":"Kidney disease and urology","slug":"kidney-disease-urology"}],"chapters":[{"id":"5036566c-74da-5f5a-8ad0-52200f66bacc","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"5b4e7fb9-e75e-5183-b93f-5121d902b8aa","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"75479619-9bb3-51b1-8d45-322a0183327c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"85bf4dec-7d92-5c07-9468-68fd460fa54c","slug":"changes","fullItemName":"Changes"},{"id":"e9caee39-e4d7-55ea-bba5-d1bfb037fab3","slug":"update","fullItemName":"Update"}]},{"id":"94be5ea4-6a52-53bd-9cff-cbc58599fb38","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"af9d912d-8cc7-598f-90cf-201a0152486f","slug":"goals","fullItemName":"Goals"},{"id":"e04a2acd-d3aa-5b29-afe8-4ff8a5cf2527","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"c36c8ae1-59b3-5370-8b7b-c879c1c25d17","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1bb64e97-bb95-5733-ba72-d5da80477d5b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0cefa383-4a3f-5e37-8c1d-0cc7b2ba971c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c308ef71-7be3-579d-9b92-dd1e9164c74d","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"34f1f543-1b43-52aa-91e6-43d392ace4b2","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"420f2db7-0bb3-5f08-a35d-671ffd9e83db","slug":"definition","fullItemName":"Definition"},{"id":"f36e5c98-76d5-563f-b7e3-a8e580d8edda","slug":"causes","fullItemName":"Causes"},{"id":"16745b88-79f5-5576-a0a4-704c8cb342e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"82584375-f9fb-5690-9fe3-f2fb2586f2de","slug":"complications","fullItemName":"Complications"},{"id":"6ddacff5-19b6-5342-b340-25aecbf26dbd","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"00dbd4ad-decc-5bde-b4a3-2599d730c702","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"cdd9f22d-7a2f-5fd6-a9e1-199b0c3ffdfa","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c6b6c8c3-633d-5062-9804-7b6711e7ddcd","slug":"assessment","fullItemName":"Assessment"},{"id":"3878fa85-9973-5158-8407-20d64dbf148d","slug":"initial-investigations","fullItemName":"Initial investigations"}]},{"id":"579baee5-96e6-5639-a5ee-7dc30540dc8f","slug":"management","fullItemName":"Management","subChapters":[{"id":"07ec0bcd-8fb7-5ae7-87fd-2ff471574c5c","slug":"management-of-chronic-kidney-disease","fullItemName":"Scenario: Management of chronic kidney disease"},{"id":"44ceaa7d-a91b-5472-a7ab-e4bc448067ad","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"b0158ce5-7a78-50df-8843-ded7d59d08e3","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"a270530d-7db1-5b03-a1d8-8ff38e242ab9","slug":"ace-inhibitors-aiiras","fullItemName":"ACE-inhibitors and AIIRAs"}]},{"id":"50985320-3b22-5997-85d2-680285318de6","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"168ee77d-eb0d-52d8-a32b-4bda877d21f0","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"c8ca80a7-ccf2-5a42-9b8e-72783e1f2131","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"fe26a3ba-fa1b-5c97-8a08-e1f7d193447a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"854a26b2-4877-59ae-863e-99abcbcad667","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"0af4d212-648e-5a4d-ad67-b1874a49688e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"f180e32d-a855-558d-b666-d4c6804afe04","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ba009e6c-4065-55da-b6c5-bd179af81374","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"cf2598e6-fd50-5f3b-8ae0-aad8ebd19ed8"}},"staticQueryHashes":["3666801979"]}